Baxter expands label of hemophilia factor IX

• The FDA approves Baxter International's (NYSE:BAX -0.6%) Rixubis [Coagulation Factor IX (Recombinant)] for routine the prophylactic treatment, control and prevention of bleeding episodes, and perioperative treatment, in children with hemophilia B. It was previously approved for use in adult patients with hemophilia B.
• Rixubis is currently under regulatory review in Europe for use in both adults and children. A decision is expected this year.